IL-17F Rat anti-Mouse, Functional Grade, Clone: RN17, eBioscience™
Rat Monoclonal Antibody
Brand: Affymetrix eBioscience 16-7473-82
Additional Details : Weight : 0.01000kg
DescriptionThe presence of the cysteine knot motif suggested the possibility of a heterodimeric structure, as was reported for TGF-beta and inhibin/activin. Recent reports confirm that co-expression of IL-17F and IL-17A in HEK293 cells results in the formation of biologically active IL-17F/IL-17A heterodimers, in addition to the IL-17F homodimers and IL-17A homodimers. Moreover, activated human CD4^+ T cells were found to produce the IL-17A/F heterodimer, along with the corresponding homodimers. In comparing the relative potency of IL-17A, IL-17F, and IL-17A/F, all three were found to induce GRO-alpha secretion; IL-17A was most potent, followed by IL-17A/F heterodimer, then IL-17F (100fold lower than IL-17A). In the mouse, the IL-17A/F heterodimer (alone or in synergy with TNF-alpha) was found to regulate the expression of IL-6 and KC (mouse homolog of human GRO-alpha); this was found to be dependent on IL-17RA and TRAF6. Applications Reported: This monoclonal antibody reacts with and inhibits the bioactivity of mouse IL-17F. Applications Tested: The ND50 of RN17 as measured by the inhibition of mouse IL-6 induction in NIH/3T3 cells is 1-6 μg/mL in the presence of 4 μg/mL of Recombinant mouse IL-17F. Neutralization dose will vary depending on assay method, cytokine concentration, and cell type. This antibody should be carefully titrated for optimal performance in the assay of interest. Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC. IL-17F (Interleukin 17F, CTLA-8)) is a cytokine belonging to the IL-17 family that is produced by inflammatory cells such as activated T cells, mast cells, and basophils. IL-17F is involved in allergic airway inflammation, and can induce several cytokines, chemokines, and adhesion molecules in bronchial epithelial cells, vein endothelial cells, fibroblasts, and eosinophils. IL-17F may be secreted as a homodimer, or a heterodimer with IL17A. It acts by binding to the type I receptor, IL-17R, aiding recruitment of monocytes and neutrophils at the site of inflammation by increasing chemokine production. IL-17F also stimulates induction of other pro-inflammatory cytokines TNF alpha, IL-1 beta, IL-6, and IL-8, and reports strongly suggest the involvement of IL-17 in several chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis. TGF-beta (differentiation) and IL-23 (expansion) are required for induction and maintece of Th17 (IL-17 producing) cells, which in turn induce the other pro-inflammatory cytokines. IL-17F is produced, and exists, as a homo-dimer, with homology to a herpes virus early protein, is one of the six members (IL-17A-F) of this cytokine family, and is well characterized and highly expressed by activated effector memory T cells. IL-17F has been found to inhibit the angiogenesis of endothelial cells and induce endothelial cells to produce IL2, TGFB1/TGFB, and monocyte chemoattractant protein-1.
|PBS with no preservative; pH 7.2|
|IL-17F, ML-1, ML1|
|Functional Assay, Neutralization|
For Research Use Only.